Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Emcure PharmaceuticalsNSE:EMCURE 41 5-Year Yield-on-Cost % is 0.15 as of Aug. 14, 2026, which is 25% below its 10-year median of 0.20. GuruFocus rates NSE:EMCURE with a GF Score™ of 41/100. The stock has 5 warning signs investors should review. Among 511 Drug Manufacturers companies, Emcure Pharmaceuticals ranks worse than 94.52% on this metric.
Emcure Pharmaceuticals's yield on cost for the quarter that ended in Jun. 2026 was 0.15.
The historical rank and industry rank for Emcure Pharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:
NSE:EMCURE'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.15 Med: 0.2 Max: 0.23
Current: 0.15
During the past 6 years, Emcure Pharmaceuticals's highest Yield on Cost was 0.23. The lowest was 0.15. And the median was 0.20.
NSE:EMCURE's 5-Year Yield-on-Cost % is ranked worse than 94.52% of 511
companies
in the Drug Manufacturers industry
Industry Median: 2.3
vs NSE:EMCURE: 0.15
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Emcure Pharmaceuticals 5-Year Yield-on-Cost % Related Terms
NSE:EMCURE vs ZTS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Emcure Pharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emcure Pharmaceuticals 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Emcure Pharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Emcure Pharmaceuticals's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Emcure Pharmaceuticals (NSE:EMCURE) has a 5-Year Yield-on-Cost % of 0.15 as of Aug. 14, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Emcure Pharmaceuticals and its competitors. This is 25% below median its historical median of 0.20. Over the past decade, Emcure Pharmaceuticals' 5-Year Yield-on-Cost % has ranged from 0.15 to 0.23. According to the industry distribution chart, Emcure Pharmaceuticals ranks #483 out of 511 companies in the Drug Manufacturers industry, placing it in the top 94.5%.
Is Emcure Pharmaceuticals' 5-Year Yield-on-Cost % too high?
Emcure Pharmaceuticals' current 5-Year Yield-on-Cost % of 0.15 is 25% below median its 10-year median of 0.20. Over the past 10 years, this metric has ranged from a low of 0.15 to a high of 0.23. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.30. Emcure Pharmaceuticals' value of 0.15 is 93.5% below this industry median. Based on the distribution chart, Emcure Pharmaceuticals ranks #483 out of 511 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Emcure Pharmaceuticals has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Emcure Pharmaceuticals' 5-Year Yield-on-Cost % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Emcure Pharmaceuticals ranks #483 out of 511 companies for 5-Year Yield-on-Cost %. This places Emcure Pharmaceuticals in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.30. Emcure Pharmaceuticals' value of 0.15 is 93.5% below this benchmark. Historically, Emcure Pharmaceuticals' own 5-Year Yield-on-Cost % has ranged from 0.15 to 0.23 over the past decade. While the company's 10-year median is 0.20 vs. the industry median of 2.30, Emcure Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.30, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Emcure Pharmaceuticals's current 5-Year Yield-on-Cost % of 0.15 is 93.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Emcure Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emcure Pharmaceuticals's current 5-Year Yield-on-Cost % is 0.15, which is 25% below median its own 10-year median of 0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emcure Pharmaceuticals stock overvalued right now?
Emcure Pharmaceuticals (NSE:EMCURE) has a current 5-Year Yield-on-Cost % of 0.15. The current 5-Year Yield-on-Cost % is 0.15, which is 25% below median its 10-year median of 0.20 and 93.5% below the Drug Manufacturers industry median of 2.30. Emcure Pharmaceuticals' overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Emcure Pharmaceuticals (NSE:EMCURE), the current 5-Year Yield-on-Cost % is 0.15 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Emcure Pharmaceuticals Ltd an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several therapeutic areas. Its portfolio includes orals including solids, liquid orals and dry syrup/suspensions., injectables such as vials and pre-filled syringes, and forms such as lyophilized & liquid and biotherapeutics. The company operates in Derma, Women's Health, Cardiovascular, Neurology, Oncology, Vaccines, and Anti-infectives. Geographically, it operates in India, Europe, Canada, Vietnam, Dubai, and Other Countries.
41GF Score
Get the complete analysis for NSE:EMCURE
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:EMCURE has been successfully added to your 
